In the context of hematologic malignancies, our study revealed that ELANE expression is significantly elevated in AML samples relative to healthy controls and correlates with poorer overall survival, thereby supporting its role as a prognostic biomarker in leukemia [40]. This evidence concerns the gene ELANE and acute myeloid leukemia.